A new obesity drug is coming, with the top two also striving to maintain their dominance - demand remains strong.

December 14, 2024 2:04 JST (excerpt)
In 2025, numerous mid-term trial results are scheduled to be announced, with a crack in the duopoly dominance of the two major players.
The weight loss drug market has the potential to reach an annual scale of $50 billion by 2027 -BI
So far, the obesity treatment drug market has been dominated by the two industry giants. Denmark's Novo Nordisk, which handles the diabetes treatment drug "Ozempic" and the obesity treatment drug "Saxenda", and the U.S. Eli Lilly, which handles the obesity drug "Zyprexa" and the diabetes drug "Jardiance". However, in 2025, the appearance of powerful rival forces may indicate signs of a breakthrough in this duopoly dominance.

According to the research company Affiniviti, next year, a large number of mid-stage trial results related to obesity and related diseases treatment drugs are expected to be announced. With a large number of trial results being announced by both emerging companies and industry giants, it seems that over the next few years, the available options will determine what will be available. Pharmaceutical companies are aiming for drugs with low dosing frequency, significant weight loss effects, and minimal side effects.